



PATENT  
454313-2334.2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Bublot et al.  
Serial No. : 10/614,481  
Filing Date : July 7, 2003  
For : EQUINE GM-CSF  
Examiner : To Be Assigned

745 Fifth Avenue  
New York, NY 10151

**EXPRESS MAIL**


Mailing Label Number: EV 195882408 US

Date of Deposit: November 5, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Mail Stop Sequence, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Charles B. Jackson

(Typed or printed name of person mailing paper or fee)

  
(Signature of person mailing paper or fee)

**RESPONSE TO COMPLY WITH REQUIREMENTS FOR  
PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This response is to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence. Applicants respectfully request acceptance of the enclosed paper copy, and the computer readable form of the Sequence listing submitted in parent application U.S. Serial No. 09/589,460, filed June 7, 2000. Accordingly, no copy of the computer readable form of the Sequence listing is submitted herewith.

**REMARKS**

The sequence listing in this application is identical to the sequence listing filed in parent application U.S. Serial No. 09/589,460, filed June 7, 2000. It is respectfully requested that the U.S.P.T.O use the electronic version of the sequence listing in the prior application, U.S. Serial No. 09/589,460, making any necessary changes therein for this application, e.g., as to Serial Number and filing date.

It is believed that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R. §1.821(f) and (g) are set forth below.

Pursuant to 37 C.F.R. §1.821(g), the undersigned attorney hereby states that this submission, filed in accordance with 37 C.F.R. §1.821(g), does not contain new matter.


Pursuant to 37 C.F.R. §1.821(f), the undersigned attorney hereby states that the content of the paper copy submitted herewith, and the computer readable copy of the Sequence listing submitted in U.S. Serial No. 09/589,460 in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

In view of the remarks and enclosures herewith, the application complies with the requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §1.821-1.825.

If any fees are required, or if any overpayment has been made, please charge such fee, or credit any overpayment, to Deposit Account 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By:   
Thomas J. Kowalski  
Reg. No. 32,147